Trial Profile
A Prospective Observational Study of Adult Patients Receiving DUPIXENT for Atopic Dermatitis
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2023
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms PROSE
- Sponsors Regeneron Pharmaceuticals; Sanofi
- 21 Mar 2023 Interim Results (n= 764) assessing Effectiveness of Dupilumab in Adult and Adolescent Patients With Atopic Dermatitis presented at the American Academy of Dermatology annual Meeting 2023
- 10 Jun 2022 Planned End Date changed from 9 Jun 2027 to 30 Mar 2027.
- 10 Jun 2022 Planned primary completion date changed from 9 Jun 2027 to 30 Mar 2027.